Abingworth completes succession
Stephen Bunting has stepped down from his role as head of Abingworth to become chairperson, replaced by Tim Haines and Kurt von Emster as joint managing partners.
Bunting has been managing partner of Abingworth since 2002. Following his transition he will remain as active member of the firm, working in a full-time capacity.
Haines joined Abingworth in 2005 as partner. Prior to that he was CEO of Abingworth portfolio company Astex Therapeutics, where he spent five years building up the company. Previously, Haines was CEO of two divisions of publicly listed medical technology company Datascope Corp. Other former senior roles include CEO of Thackray and general manager of Baxter UK.
Current and past board positions include Astex Pharmaceuticals, Fovea, Kspine, Lomboard Medical, Pixium Vision, PowderMed, Sientra, Stanmore Implants and XCounter.
Von Emster joined the life sciences- and healthcare-focused GP in January 2015 as partner. Based in Menlo Park, he was previously a co-founder of US investment firm venBio. He has also worked with MPM Capital and Franklin Templeton.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









